Structures by: Spillman M. J.
Total: 9
Indomethacin Nicotinamide (1/1)
C19H16ClNO4,C6H6N2O
CrystEngComm (2013) 15, 20 4041
a=17.1980(8)Å b=5.0156(2)Å c=27.3815(15)Å
α=90° β=97.311(2)° γ=90°
5H-dibenz(b,f)azepine-5-carboxamide 2-(1-((4- chlorophenyl)carbonyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetic acid (1/1)
C15H12N2O1,C19H16Cl1N1O4
CrystEngComm (2011) 13, 21 6327
a=10.2447(3)Å b=29.148(1)Å c=10.2114(3)Å
α=90° β=106.636(2)° γ=90°
C15H13ClN2O
C15H13ClN2O
Crystal Growth & Design (2013) 13, 11 5121
a=7.6241(3)Å b=9.5476(4)Å c=17.8401(7)Å
α=90.00° β=90.00° γ=90.00°
C16H16.6Cl0.4NO2.6
C16H16.6Cl0.4NO2.6
Crystal Growth & Design (2013) 13, 11 5121
a=20.2651(9)Å b=5.8463(3)Å c=23.8489(9)Å
α=90.00° β=95.724(4)° γ=90.00°
C15H13BrN2O
C15H13BrN2O
Crystal Growth & Design (2013) 13, 11 5121
a=7.8120(2)Å b=9.5016(3)Å c=18.0400(7)Å
α=90.00° β=90.00° γ=90.00°
C15H15BrN2O2
C15H15BrN2O2
Crystal Growth & Design (2013) 13, 11 5121
a=5.0943(11)Å b=11.110(2)Å c=26.065(5)Å
α=90.00° β=91.646(19)° γ=90.00°
C15H15.5Cl0.5N2O2.5
C15H15.5Cl0.5N2O2.5
Crystal Growth & Design (2013) 13, 11 5121
a=29.4803(17)Å b=4.9462(2)Å c=21.6558(13)Å
α=90.00° β=119.462(8)° γ=90.00°
C15H13ClN2O
C15H13ClN2O
Crystal Growth & Design (2013) 13, 11 5121
a=14.1099(3)Å b=17.4778(3)Å c=5.3403(2)Å
α=90.00° β=90.00° γ=90.00°
C15H13BrN2O
C15H13BrN2O
Crystal Growth & Design (2013) 13, 11 5121
a=5.3472(2)Å b=10.3235(3)Å c=49.6238(17)Å
α=90.00° β=90.00° γ=90.00°